NASDAQ: PCRX · Specialty & Generic Drug Manufacturers
Pacira BioSciences (PCRX) fair value and price range
As of 14 Nov 2026, Faircurve's model values Pacira BioSciences (PCRX) at $36.71 a share. The stock last closed at $36.48, which puts the model's fair value 0.6% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Pacira BioSciences, Inc.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $36.71, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $36.48 is 0.6% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 4 Mar 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give PCRX?
The calibrated range for PCRX over 63 trading days is $29.36 to $43.61. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $23.20 to $56.01. In 51% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Pacira BioSciences, Inc. (PCRX) operates within the United States. The company is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health.
Faircurve's model put the fair value at $36.71 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $36.68, so the fair value moved +0.1%. The calibrated range over 63 trading days is $29.36 to $43.61. It is built from the fair value, since there is no live options data for the stock, and calibrated weekly against realised prices from 13,250 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade looks at input completeness, the number and agreement of comparable companies, and the width of the range. It does not say whether the fair value is right.
The model compares the company with ANI Pharmaceuticals, Inc. (ANIP) and Alkermes plc (ALKS), both with fair values on the site. Six further comparable companies have no verdict on this date: Phibro Animal Health Corporation (PAHC), Amphastar Pharmaceuticals, Inc. (AMPH), Supernus, Inc. (SUPN), Collegium Pharmaceutical, Inc. (COLL), Lantheus Holdings, Inc. (LNTH) and Amneal Pharmaceuticals, Inc. (AMRX). This run's facts do not include a quality score against peers.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does PCRX report earnings, and how has the stock reacted?
Pacira BioSciences's next earnings report is scheduled for 4 Mar 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PCRX's last 8 reports, ignoring direction, was 2.6%.
How does PCRX compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Pacira BioSciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PAHC Phibro Animal Health Corporation | $35.02 | $36.25 | +3.5% | Low evidence grade |
| ANIP ANI Pharmaceuticals, Inc. | $70.89 | $78.16 | +10.3% | Fairly valued |
| AMPH Amphastar Pharmaceuticals, Inc. | $29.17 | $29.56 | +1.3% | Low evidence grade |
| SUPN Supernus, Inc. | $28.83 | $29.86 | +3.6% | Low evidence grade |
| COLL Collegium Pharmaceutical, Inc. | $25.43 | $25.54 | +0.4% | Low evidence grade |
| LNTH Lantheus Holdings, Inc. | $101.72 | $100.47 | -1.2% | Data under review |
| AMRX Amneal Pharmaceuticals, Inc. | $21.23 | $19.34 | -8.9% | Low evidence grade |
| ALKS Alkermes plc | $46.53 | $46.51 | 0.0% | Fairly valued |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
Pacira BioSciences at a glance
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health.
- Market value
- $1.5B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $785M
- Consensus revenue growth, next fiscal year
- +3.5%
- Analysts with estimates
- 5
- Beta to the US market
- -0.01
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Pacira BioSciences on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for PCRX was $36.68. As of 14 Nov 2026 it is $36.71, a change of +0.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Pacira BioSciences's valuation
Is Pacira BioSciences stock undervalued or overvalued?
Faircurve's model puts PCRX's fair value at $36.71 a share against a last close of $36.48, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is PCRX's fair value?
$36.71 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $23.20 to $56.01.
What price range does the model give PCRX?
$29.36 to $43.61 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Pacira BioSciences report earnings next?
The next report is scheduled for 4 Mar 2027. Companies can move their dates.
How much has PCRX moved on past earnings reports?
Across its last 8 reports the median two session move was 2.6%, ignoring direction. The largest was -7.6% around the report of 4 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for PCRX is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on PCRX
The model holds no idea open on PCRX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PCRX with their outcomes. A free account is enough.